Solutions Support Endpoint Reliability In Pediatric Rare Disease Trial

A pharmaceutical sponsor embarked on a pivotal trial to explore a new treatment for a rare pediatric disease. Ensuring the precision and dependability of their endpoint data was paramount. Recognizing the limitations of their current vendor, the sponsor enlisted Signant to provide solutions and services dedicated to enhancing endpoint reliability.

As recognized global leaders in CNS, rare disease, and pediatric trials, Signant was well-prepared with established solutions, scientific proficiency, and a track record of salvaging studies to assume a leading role.

Through a strategic overhaul of the sponsor's rater training initiative and the application of Signant's Blinded Data Analytics solution, the team was able to meticulously validate complex assessment data, ensuring its accuracy and suitability for regulatory scrutiny. This endeavor culminated in the FDA's approval of the pioneering treatment for the rare pediatric ailment.

For more comprehensive insights, delve into the case study, and reach out to their team if your trials require expert intervention.